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Abstract - Although macrolides are widely used for treating pneumococcal infections, an increase in macrolide resistance 
might compromise their use. The objective of this study was to determine the prevalence of macrolide-resistant pheno-
types and genotypes in macrolide-resistant S. pneumoniae isolates in Serbia. A total of 228 macrolide-resistant strains 
isolated during the period of 2009-2012, were analyzed. Macrolide resistance phenotypes were determined by a double 
disk diffusion test. The presence of macrolide resistance genes was detected by PCR. Antibiotics susceptibilities were tested 
using the VITEK2 system and E test. Among the examined isolates, the MLSB phenotype which is linked to the presence 
of the erm(B) gene dominated (83.3%), while the mef(A) gene which is associated with the M phenotype, was identified 
in 16.7% isolates. Over 40% of isolates expressed co-resistance to penicillin. A multiple-resistant pattern was found in 
36.4% strains, more frequently in children. However, all strains were susceptible to telithromycin, vancomycin, linezolid, 
fluoroquinolones and rifampicin.
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INTRODUCTION
Streptococcus pneumoniae is a leading cause of dis-
eases,  inducing  invasive  (meningitis,  septicemia, 
bacteremic  pneumonia)  and  mucosal  infections 
(otitis media, sinusitis) in both children and adults 
worldwide (Centers for Disease Control and Preven-
tion, 2000; Robinson et al., 2001; Farha, 2005). In ad-
dition, pneumococcus is the most common causes of 
community-acquired pneumonia (CAP) (Ortqvist et 
al., 2005; Marrie, 2001). 
Beta lactam and macrolide antibiotics have re-
mained  a  first  choice  for  the  empirical  treatment 
of pneumococcal infections (Whitney et al., 2000). 
However, in recent decades, the treatment of pneu-
mococcal infections is becoming more difficult due 
to a global increase and expansion of pneumococcal 
resistance to these antibiotics. This is of particular 
importance, since strains exhibiting penicillin and 
macrolide are frequently resistant to other classes of 
antibiotics. The prevalence of resistance varies great-
ly among countries (Lynch et al., 2005).
Macrolide  resistance  in  Streptococcus  pneumo-
niae is mediated by two major mechanisms – ribos-
omal methylation encoded by the erm(B) gene and 
the drug efflux, encoded by the mef(A) gene. Modi-
fication of ribosomal targets leads to cross-resistance 
to  macrolides,  lincosamides  and  streptogramin  B 100 MIRJANA HADNAĐEV ET AL.
(MLSB phenotype) (Douthwaite et al, 2000; Hansen et 
al., 2002; Kresken et al., 2004). This phenotype can be 
either inducibly (iMLSB) or constitutively expressed 
(cMLSB). Drug efflux confers resistance to 14- and 
15-membered macrolides (M phenotype). 
There are few data concerning the pneumococ-
cal resistance to macrolides in Serbia. The aim of this 
study was to examine the prevalence of macrolide-
resistant phenotypes and genotypes among invasive 
and noninvasive macrolide-resistant S. pneumoniae 
isolates in Serbia.
MATERIALS AND METHODS
A total of 228 invasive and non-invasive macrolide-
resistant pneumococcal strains (one strain per pa-
tient) were analyzed. The strains were isolated in 16 
laboratories  throughout  Serbia,  during  2009-2012, 
and  sent  for  further  investigation  to  the  National 
Reference Laboratory for Streptococci and Pneumo-
cocci, Institute for Microbiology and Immunology, 
Medical Faculty, Belgrade. Out of 228 isolates, 34 
(14.9%) were derived from invasive infections, while 
194 (85.1%) came from noninvasive infections. In-
vasive  isolates  were  obtained  from  blood  (n=19), 
cerebrospinal fluid (n=13), and pleural fluid (n=2). 
Non-invasive isolates were cultured from nose swab 
(n=173), sputum (n=8), ear swabs (n=6), conjucti-
val swabs (n=5), and bronchial and tracheal aspirates 
(n=2). Isolates were obtained from children ≤16 years 
old (n=157) and adults >16 years of age (n=71). 
Pneumococcal isolates were identified by alpha 
hemolysis  and  colony  morphology  on  5%  sheep 
blood  agar,  Gram  stain  characteristics,  optochin 
sensitivity  (BioRad,  USA),  slide  agglutination  test 
(bioMerieux, France) and bile solubility. The strains 
were stored at -80ºC.
Macrolide  resistance  phenotypes  were  deter-
mined by a double disk diffusion test using eryth-
romycin  (15μ)  and  clindamycin  (2μg)  disks  (bio-
Rad,  USA),  as  described  elsewhere  (Montanari  et 
al., 2003). The absence of an inhibition zone around 
both disks suggested cross-resistance to macrolides-
lincosamides-streptogramin  B  (cMLS  phenotype). 
Blunting of the clindamycin inhibition zone proxi-
mal to the erythromycin disk indicated inducible re-
sistance (iMLSB). Susceptibility to clindamycin with 
resistance to erythromycin suggested the M pheno-
type (Calatayud et al., 2007; Van der Linden et al., 
2007).
Macrolide resistance genes – erm(B) and mef(A) 
–  were  determined  by  PCR.  Previously  published 
primers for mefA and ermB were used (Farell et al., 
2001).
Amplification was performed using the following 
conditions: initial denaturation at 95⁰C for 10 min, 
followed by 35 cycles at 95⁰C for 30 s, 59⁰C for 30 s 
and 72⁰C for 30 s. Final elongation was performed at 
72⁰C for 10 min.
The antibiotic susceptibilities against 19 antibi-
otics were tested by VITEK2 (bioMerieux, France) 
automated system (bio Merieux, France,card AST-
P576).  Minimal  inhibitory  concentrations  (MICs) 
of erythromycin, clindamycin, penicillin and ceftri-
axone were determined by the E test (bioMerieux, 
France). Streptococcus pneumoniae ATCC 49619 was 
used as a quality control strain. The obtained results 
were interpreted according to CLSI guidelines (CLSI, 
2013).
The  statistical  analysis  was  performed  using 
SPSS software, version 13.0. The chi-square test was 
applied when appropriate. P values of 0.05 were con-
sidered statistically significant.
RESULTS
Among 228 macrolide-resistant isolates, 190 (83.3%) 
exhibited the MLSB phenotype: 182 (79.8%) belonged 
to the cMLS, and 8 (3.5%) to the iMLS phenotype. 
The remaining 38 isolates (3.5%) were confirmed as 
M phenotype.
The  prevalence  of  MLS  resistance  was  82.3% 
(28/34) in invasive isolates and 83.5% (162/194) in 
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type was predominant in both age groups; 87.9% in 
children and 73.2%.in adults. 
The distribution of erm(B) and mef(A) resistance 
genes is presented in Table 2. In 178 (82.4%) of 216 
tested strains, the erm(B) gene was identified, while 
the mef(A) gene was found in 39 (18.1%). All the 
strains assigned to the MLSB phenotype harbored the 
erm(B) gene, while all the strains with M phenotype 
had the mef(A) gene. The presence of both resistance 
genes was confirmed in one strain with MLSB phe-
notype.
Table 1. Distribution of resistance phenotypes in erythromycin-resistant S. pneumoniae invasive (n=34 ) and noninvasive (n=194) 
strains collected from children and adults.
Phenotypes
Children (n=157) Adults (n=71) Total
invasive (n) noninvasive (n) invasive (n) noninvasive (n)
cMLS 15 118 11 38 182
iMLS 0 5 2 1 8
M 3 16 3 16 38
Total  18 139 16 55 228
Table 2. Distribution of resistance related genes in 216 tested macrolide-resistant pneumococci.
Phenotypes erm(B) mef(A)
cMLS 170 1
iMLS 8 0
M 0 38
Table 3. Distribution of macrolide resistance phenotypes and MIC ranges for erythromycin, clindamycin, penicillin and ceftriaxone.
Phenotype n (%) Antibiotics
MIC (µg/ml)
Range                         50%                     90%
cMLS
182 (79.8)
Erythromycin 4->256 >256 >256
Clindamycin 4->256 >256 >256
Penicillin 0.06-8 1 3
Ceftriaxone 0.06-4 1 2
iMLS
8 (3.5)
Erythromycin 3->256 >256 >256
Clindamycin 0.064-≥256 2 8
Penicillin 0.06-3 0.5 2
Ceftriaxone 0.06-2 0.5 1
M
38 (16.7)
Erythromycin 1.5->256 3 4
Clindamycin 0.016-0.25 0.25 0.25
Penicillin 0.06-2 0.25 1
Ceftriaxone 0.06-2 0.25 1102 MIRJANA HADNAĐEV ET AL.
The  MLSB/erm(B)  positive  strains  demon-
strated  a  high  level  of  resistance  to  erythromycin 
(MIC50>256µg/ml), while M/mefA-positive isolates 
expressed moderate resistance (MIC50=3µg/ml) (Ta-
ble 3). Almost all (98.9%) erm(B)-positive isolates 
were resistant to clindamycin (MIC50>256µg/ml). A 
low  percentage  of  clindamycin-susceptible  strains 
(1.1%) among the erm(B)-positive isolates belonged 
to the iMLSB phenotype. All M/mef(A) strains were 
susceptible to clindamycin (MIC50=0.25µg/ml).
Among  macrolide-resistant  strains,  penicil-
lin  and  third  generation  cephalosporin  (cefotaxi-
me, ceftriaxone) nonsusceptibility was observed in 
43.9% and 23.2%, respectively. Significantly, higher 
resistance rates to both antibiotics were observed in 
children than in adults (21.1%) (Table 4). The non-
invasive strains proved to be more resistant than the 
invasive ones, but the difference was not statistically 
significant.
More than one-third (36.4%) of macrolide-re-
sistant strains showed co-resistance to at least one 
of the following agents: penicillin, tetracycline and 
trimethoprim-sulfamethoxazole. Multiresistant iso-
lates were significantly more prevalent among chil-
dren (45.9%) than adults (15.5%) (Table 4).
The rates of resistance to trimethoprim-sulfame-
thoxazole and tetracycline were high – 71% and 82%, 
respectively. On the other hand, all strains were fully 
susceptible to telithromycin, vancomycin, linezolid, 
fluoroquinolones and rifampicin.
DISCUSSION
The results of our study showed that a constitutive 
MLSB phenotype  predominates  among  macrolide-
resistant S. pneumoniae isolates in Serbia. Although 
a high rate of macrolide resistance in pneumococci 
in Serbia (41%) was previously demonstrated (Gajić 
et al., 2012), it is of particular concern, since the iso-
lates with cMLSB phenotype are highly resistant to 
all macrolide-lincosamide-streptogramin antibiotics 
(Leclercq et al., 2002). These strains exhibit very high 
MICs  to  erythromycin  (MIC50>256µg/ml),  which 
was also demonstrated in our study. 
The analysis of resistance genes has shown that 
the ermB gene, which encodes methylation of 23S 
rRNA,  is  present  in  the  majority  (82.4%)  of  our 
strains. Globally, the erm(B) gene is the most com-
mon macrolide resistance determinant in pneumo-
cocci. A high prevalence of the erm(B) gene is regis-
tered in Belgium (91%), France (90%), Spain (88%), 
Hungary (82%). Poland (80%), China (77%), Italy 
(56%) and Japan (58%) (Felmingham et al., 2007). 
Conversely, the mef(A) gene is the prevailing mac-
rolide resistance mechanism in USA (66%), Austral-
ia, Germany, Greece, Finland, Ireland and UK (Far-
rell et al., 2008).
In  recent  years,  the  number  of  pneumococcal 
strains with a dual resistance mechanism related to 
the presence of both erm(B) and mef(A) genes has 
increased globally and the prevalence of these strains 
reaches up to 12% (Farrell et al., 2008). The countries 
Table 4. The most common patterns of co-resistance and multiresistance in macrolide-resistant pneumococci.
Resistance profile
Children
(n= 157)
Adults
(n=71 )
p χ2 % %
Macrolide and penicillin co-resistance 
(I+R)
54.1 21.1 0.001 21.64
Macrolide and cefotaxime (I+R)
co-resistance
29.9 8.5 0.001 12.65
Multiresistance (ERY+PEN+TET+SXT) 45.9 15.5 0.001 19.47
*I-intermediate, R-resistant, PEN-penicillin, TET-tetracycline, SXT-trimethoprim-sulfamethoxazole.PHENOTYPES AND GENOTYPES OF MACROLIDE-RESISTANT STREPTOCOCCUS PNEUMONIAE IN SERBIA 103
with a high prevalence of the dual resistance mecha-
nism in pneumococci are South Korea, South Africa, 
USA and Australia. The majority of these strains are 
multiresistant  and  clonally  related  (Jenkins  et  al., 
2008; McGee et al., 2001) and their spreading is wor-
rying. In our study, the dual resistance mechanism 
was detected in only 1 out of 216 macrolide-resistant 
strains, suggesting it is uncommon in Serbia.
Of note is our finding that pneumococcal mac-
rolide resistance in Serbia is frequently associated 
with resistance to other antibiotics. We observed a 
high rate of penicillin nonsusceptible pneumococci 
(PNSP)  among  MRSP  (43.9%)  and  a  significant 
difference  in  the  prevalence  of  PNSP  in  children 
(54.1%) compared to adults (21.1%). Similar find-
ings  were  reported  from  other  regions  (Brown  et 
al., 2004; Dias et al., 2006; Farrell et al., 2008). The 
explanation for these results could be the overuse of 
antibiotics in children since localized pneumococcal 
infections are more common in this age group. Most 
pediatric invasive strains were isolated from menin-
gitis cases and criteria that are more stringent were 
used in defining penicillin nonsusceptibility (CLSI, 
2012). Therefore, pediatric patients revealed signifi-
cantly higher penicillin resistance rates. 
The  prevalence  of  pneumococcal  penicillin 
and macrolide dual nonsusceptibility varies greatly 
among countries (Felmingham et al., 2007). Percent-
ages ranged from zero (Estonia, Germany and Latvia) 
to 44.4% (Romania) (EARS-Net, 2011).
In our study, resistance to 3rd generation cepha-
losporins was present in 23.2% of the isolates, and 
it was more common in children (29.9%) than in 
adults (8.5%). The resistance of our strains to tet-
racycline  and  trimethoprim-sulfamethoxazole  was 
exceptionally high – 82% and 71%, respectively. As 
tetracycline resistance determinants are located on 
the same transposons as the erm(B) gene, pneumo-
coccal resistance to tetracyclines is commonly asso-
ciated with their macrolide resistance. It is therefore 
evident that high levels of tetracycline resistance are 
often reported in the countries with a high level of 
macrolide resistance (Cochetti et al., 2008; Seral et 
al., 2001). Multiresistant phenotype – co-resistance 
to penicillin, macrolides, tetracycline and trimetho-
prim-sulfamethoxazole, was registered in up to 30% 
of our MRSP strains and again more often in chil-
dren. 
It should be stressed out that our strains were 
fully susceptible to telithromycin, vancomycin, line-
zolid, fluoroquinolones and rifampicin. These antibi-
otics are used for empiric treatment of community-
acquired pneumonia (telithromycin, levofloxacin) or 
infections caused by resistant pneumococcal strains. 
The  introduction  of  PCV7  into  the  childhood 
immunization schedule in European countries and 
the USA resulted in a significant reduction in the in-
cidence of invasive pneumococcal diseases in chil-
dren aged ≤5 years due to vaccine serotypes (Pilish-
vili et al., 2010). The use of PCV7 also reduced the 
pneumococcal resistance in the vaccinated, as well 
as non-vaccinated groups. There is strong evidence 
that a significant decline in overall penicillin non-
susceptibility, particularly in children, was registered 
in Spain, the USA and other countries (Fenoll et al., 
2009) in the recent period, which was probably due 
to a heptavalent conjugate vaccine (PCV7) imple-
mentation and decrease in antibiotic consumption 
(EARSS  2010).  Pneumococcal  conjugate  vaccines 
are recommended in Serbia, but not reimbursed, and 
vaccine coverage is low. We assume that only after 
its introduction into the national immunization pro-
grams could some reduction in pneumococcal resist-
ance in Serbia be expected.
It could be concluded that the constitutive MLSB/
erm(B) phenotype/genotype is predominant among 
macrolide-resistant pneumococcal strains in Serbia. 
The frequency of co-resistance to penicillin, as well 
as the frequency of the multiple resistance, is high. 
Future studies on macrolide resistance and its rela-
tion to specific serotypes are necessary and foreseen.
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